
Pfizer Jettisons FDA-Approved Hemophilia B Gene Therapy Beqvez
Pfizer has made the decision to discontinue development and commercialization of fidanacogene elaparvovec (Beqvez), an FDA-approved adeno-associated virus (AAV) vector-based gene therapy for the treatment of hemophilia B.1 According to a statement from a …